Key achievements included positive Phase 3 ASPEN data for brensocatib in bronchiectasis, record-breaking ARIKAYCE revenues, and advancements in other pipeline programs such as TPIP and ARIKAYCE's ...

Patients treated with on dupilumab showed significant improvement in sustained BP remission compared with those on placebo.

Asthma a chronic respiratory condition may be driven by specific immune cells that influence inflammation and severity ...